No Data
No Data
Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency
Buy Rating on Inozyme Pharma: Promising Potential of INZ-701 and Market Opportunity
Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference
Wedbush Maintains Inozyme Pharma(INZY.US) With Buy Rating, Cuts Target Price to $7
Wells Fargo Maintains Inozyme Pharma(INZY.US) With Buy Rating, Cuts Target Price to $9
Express News | Piper Sandler Maintains Overweight on Inozyme Pharma, Lowers Price Target to $23
BelleWeather : I hold a position in Inzy. Very much a wildcard, business specific and macro. I hold OTM calls 12/25 though, plus shares. Still bullish.